Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium thiosulphate to reduce cisplatin-induced ototoxicity in standard-risk hepatoblastoma
2007-002402-21Phase 3Completed
- Sponsor
- University of Birmingham
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sodium thiosulfate in hepatoblastoma (2 arms), sponsored by University of Birmingham. Primary endpoint: Rate of Brock grade ≥1 hearing loss. Started Jun 2007; status: completed.
02
Drugs
sodium thiosulfate
03
Conditions
hepatoblastoma
Beyond the preview
Go deeper on 2007-002402-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002402-21.